Symbols / BFRI $0.83 +0.73%
BFRI Chart
About
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 9.67M |
| Enterprise Value | 11.08M | Income | -17.57M | Sales | 37.16M |
| Book/sh | -0.22 | Cash/sh | 0.29 | Dividend Yield | — |
| Payout | 0.00% | Employees | 92 | IPO | — |
| P/E | — | Forward P/E | -3.61 | PEG | — |
| P/S | 0.26 | P/B | -3.74 | P/C | — |
| EV/EBITDA | -0.63 | EV/Sales | 0.30 | Quick Ratio | 0.51 |
| Current Ratio | 1.15 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.50 | EPS next Y | -0.23 | EPS Growth | — |
| Revenue Growth | -22.50% | Earnings | 2026-03-18 | ROA | -64.91% |
| ROE | -11.92% | ROIC | — | Gross Margin | 64.41% |
| Oper. Margin | -89.84% | Profit Margin | -47.28% | Shs Outstand | 11.65M |
| Shs Float | 7.95M | Short Float | 3.83% | Short Ratio | 0.57 |
| Short Interest | — | 52W High | 1.19 | 52W Low | 0.54 |
| Beta | 0.63 | Avg Volume | 483.36K | Volume | 46.80K |
| Target Price | $6.00 | Recom | Strong_buy | Prev Close | $0.82 |
| Price | $0.83 | Change | 0.73% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.00
Mean price target
2. Current target
$0.83
Latest analyst target
3. DCF / Fair value
$-6.98
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.83
Low
$3.00
High
$9.00
Mean
$6.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-19 | main | Benchmark | Buy → Buy | $3 |
| 2024-11-15 | reit | Benchmark | Buy → Buy | $7 |
| 2024-08-16 | reit | Benchmark | Buy → Buy | $7 |
| 2023-08-31 | reit | Benchmark | Buy → Buy | $18 |
- Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why - Yahoo Finance Mon, 09 Mar 2026 16
- Can BFRI stock weather global recession - 2025 Earnings Impact & Weekly Stock Breakout Alerts - Naître et grandir Sat, 07 Mar 2026 13
- Light therapy gel clears more actinic keratoses on limbs, neck - Stock Titan Mon, 09 Feb 2026 08
- Biofrontera Reports Positive Phase 2b Acne Trial Results - TipRanks Mon, 09 Mar 2026 13
- There's No Escaping Biofrontera Inc.'s (NASDAQ:BFRI) Muted Revenues Despite A 42% Share Price Rise - simplywall.st Fri, 23 Jan 2026 08
- Biofrontera Inc. (BFRI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq hu, 05 Feb 2026 08
- Is Biofrontera Inc. (BFRI) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance hu, 05 Feb 2026 08
- U.S. patent board backs Biofrontera in battle over Sun Pharma patent - Stock Titan hu, 26 Feb 2026 08
- Biofrontera Emerges as Stronger Biotech Stock Compared to RenovaCare - National Today Wed, 18 Feb 2026 08
- Record $17M quarter for Biofrontera as Ameluz PDT sales climb higher - Stock Titan ue, 13 Jan 2026 08
- Biofrontera Wins Key PTAB Ruling in Sun Patent Dispute - TipRanks hu, 26 Feb 2026 08
- Biofrontera Stock Falls 8% Despite Positive Data From Ameluz PDT Study - Nasdaq Mon, 09 Feb 2026 08
- Biofrontera's light-based option for common skin cancer under FDA review - Stock Titan Wed, 11 Feb 2026 08
- Biofrontera Receives Nasdaq Notice on Bid Price Noncompliance - TipRanks Wed, 07 Jan 2026 08
- Biofrontera Cuts Ameluz Royalties From 35% to 12%, Gains Full US Control with $11M Backing - Stock Titan Mon, 30 Jun 2025 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|
| 0 | 137500 | — | — | LUEBBERT HERMANN | Chief Executive Officer | — | 2026-03-05 00:00:00 | D |
| 1 | 87500 | — | — | LEFFLER EUGENE FREDERICK | Chief Financial Officer | — | 2026-03-05 00:00:00 | D |
| 2 | 137500 | — | — | LUEBBERT HERMANN | Chief Executive Officer | — | 2025-09-10 00:00:00 | D |
| 3 | 87500 | — | — | LEFFLER EUGENE FREDERICK | Chief Financial Officer | — | 2025-09-10 00:00:00 | D |
| 4 | 4771 | — | — | LUEBBERT HERMANN | Chief Executive Officer | — | 2024-05-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 325.50K | 634.83K | 4.60M | -3.28M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -16.03M | -21.48M | -20.97M | -24.61M |
| TotalUnusualItems | 1.55M | 3.02M | 21.91M | -12.15M |
| TotalUnusualItemsExcludingGoodwill | 1.55M | 3.02M | 21.91M | -12.15M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -17.76M | -20.13M | -640.00K | -37.71M |
| ReconciledDepreciation | 1.15M | 1.06M | 1.17M | 540.00K |
| ReconciledCostOfRevenue | 18.61M | 17.44M | 15.19M | 12.74M |
| EBITDA | -14.48M | -18.45M | 934.00K | -36.76M |
| EBIT | -15.63M | -19.52M | -238.00K | -37.30M |
| NetInterestIncome | -2.08M | -560.00K | -203.00K | -344.00K |
| InterestExpense | 2.11M | 600.00K | 370.00K | 360.00K |
| InterestIncome | 71.00K | 132.00K | 175.00K | 16.00K |
| NormalizedIncome | -18.98M | -22.52M | -17.95M | -28.84M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -17.76M | -20.13M | -640.00K | -37.71M |
| TotalExpenses | 54.53M | 56.65M | 51.05M | 49.95M |
| TotalOperatingIncomeAsReported | -17.21M | -22.68M | -18.58M | -25.20M |
| DilutedAverageShares | 5.52M | 1.55M | 1.33M | 440.41K |
| BasicAverageShares | 5.52M | 1.55M | 1.33M | 440.41K |
| DilutedEPS | -3.22 | -13.02 | -0.48 | -85.60 |
| BasicEPS | -3.22 | -13.02 | -0.48 | -85.60 |
| DilutedNIAvailtoComStockholders | -17.76M | -20.13M | -640.00K | -37.71M |
| NetIncomeCommonStockholders | -17.76M | -20.13M | -640.00K | -37.71M |
| NetIncome | -17.76M | -20.13M | -640.00K | -37.71M |
| NetIncomeIncludingNoncontrollingInterests | -17.76M | -20.13M | -640.00K | -37.71M |
| NetIncomeContinuousOperations | -17.76M | -20.13M | -640.00K | -37.71M |
| TaxProvision | 22.00K | 14.00K | 32.00K | 56.00K |
| PretaxIncome | -17.74M | -20.12M | -608.00K | -37.66M |
| OtherIncomeExpense | 1.55M | 3.02M | 21.98M | -11.46M |
| OtherNonOperatingIncomeExpenses | -1.00K | -3.00K | 69.00K | 689.00K |
| SpecialIncomeCharges | -148.00K | 7.42M | 3.80M | 650.00K |
| OtherSpecialCharges | 148.00K | -7.52M | ||
| RestructuringAndMergernAcquisition | 0.00 | 100.00K | -3.80M | -650.00K |
| GainOnSaleOfSecurity | 1.70M | -4.40M | 18.11M | -12.80M |
| NetNonOperatingInterestIncomeExpense | -2.08M | -560.00K | -203.00K | -344.00K |
| TotalOtherFinanceCost | 41.00K | 92.00K | 8.00K | |
| InterestExpenseNonOperating | 2.11M | 600.00K | 370.00K | 360.00K |
| InterestIncomeNonOperating | 71.00K | 132.00K | 175.00K | 16.00K |
| OperatingIncome | -17.21M | -22.58M | -22.38M | -25.85M |
| OperatingExpense | 35.92M | 39.20M | 35.87M | 37.21M |
| ResearchAndDevelopment | 2.09M | 77.00K | 0.00 | |
| SellingGeneralAndAdministration | 33.84M | 39.13M | 35.87M | 37.21M |
| GeneralAndAdministrativeExpense | 39.13M | 35.87M | 37.21M | |
| OtherGandA | 39.13M | 35.87M | 37.21M | |
| GrossProfit | 18.71M | 16.63M | 13.49M | 11.36M |
| CostOfRevenue | 18.61M | 17.44M | 15.19M | 12.74M |
| TotalRevenue | 37.32M | 34.07M | 28.67M | 24.10M |
| OperatingRevenue | 37.32M | 34.07M | 28.67M | 24.10M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 8.87M | 1.52M | 1.33M | 855.24K |
| ShareIssued | 8.87M | 1.52M | 1.33M | 855.24K |
| NetDebt | 2.56M | |||
| TotalDebt | 4.92M | 5.40M | 1.35M | 0.00 |
| TangibleBookValue | 4.40M | 2.16M | 20.85M | 7.89M |
| InvestedCapital | 8.53M | 8.70M | 23.88M | 11.34M |
| WorkingCapital | 8.68M | 4.99M | 22.25M | 32.59M |
| NetTangibleAssets | 4.40M | 2.16M | 20.85M | 7.89M |
| CapitalLeaseObligations | 824.00K | 1.50M | 1.35M | 0.00 |
| CommonStockEquity | 4.43M | 4.79M | 23.88M | 11.34M |
| TotalCapitalization | 8.53M | 4.79M | 23.88M | 11.34M |
| TotalEquityGrossMinorityInterest | 4.43M | 4.79M | 23.88M | 11.34M |
| StockholdersEquity | 4.43M | 4.79M | 23.88M | 11.34M |
| RetainedEarnings | -117.41M | -99.65M | -79.52M | -78.88M |
| AdditionalPaidInCapital | 121.83M | 104.44M | 103.40M | 90.20M |
| CapitalStock | 9.00K | 2.00K | 1.00K | 17.00K |
| CommonStock | 9.00K | 2.00K | 1.00K | 17.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 17.67M | 23.14M | 27.01M | 41.88M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 5.65M | 5.05M | 6.11M | 28.05M |
| OtherNonCurrentLiabilities | 23.00K | 37.00K | 21.00K | 5.65M |
| DerivativeProductLiabilities | 1.25M | 4.21M | 2.84M | 12.85M |
| NonCurrentDeferredLiabilities | 0.00 | 2.40M | 9.54M | |
| NonCurrentDeferredRevenue | 0.00 | 2.40M | 9.54M | |
| LongTermDebtAndCapitalLeaseObligation | 4.37M | 804.00K | 848.00K | 0.00 |
| LongTermCapitalLeaseObligation | 276.00K | 804.00K | 848.00K | 0.00 |
| LongTermDebt | 4.10M | |||
| CurrentLiabilities | 12.02M | 18.09M | 20.89M | 13.84M |
| OtherCurrentLiabilities | 613.00K | 686.00K | 372.00K | 829.00K |
| CurrentDeferredLiabilities | 0.00 | 6.94M | 3.24M | |
| CurrentDeferredRevenue | 0.00 | 6.94M | 3.24M | |
| CurrentDebtAndCapitalLeaseObligation | 548.00K | 4.59M | 498.00K | |
| CurrentCapitalLeaseObligation | 548.00K | 691.00K | 498.00K | 0.00 |
| CurrentDebt | 3.90M | |||
| OtherCurrentBorrowings | 3.90M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.43M | 2.19M | 2.85M | 2.38M |
| CurrentProvisions | 58.00K | 149.00K | 82.00K | 246.00K |
| PayablesAndAccruedExpenses | 8.37M | 10.47M | 10.15M | 7.13M |
| CurrentAccruedExpenses | 1.17M | 1.47M | 7.56M | 6.20M |
| Payables | 7.20M | 9.01M | 2.59M | 940.00K |
| DuetoRelatedPartiesCurrent | 5.34M | 5.70M | 1.31M | 282.00K |
| AccountsPayable | 1.86M | 3.31M | 1.28M | 658.00K |
| TotalAssets | 22.10M | 27.93M | 50.88M | 53.22M |
| TotalNonCurrentAssets | 1.40M | 4.86M | 7.74M | 6.80M |
| OtherNonCurrentAssets | 383.00K | 482.00K | 320.00K | 268.00K |
| DuefromRelatedPartiesNonCurrent | 0.00 | 2.81M | 2.81M | |
| NonCurrentAccountsReceivable | 2.81M | 2.81M | ||
| GoodwillAndOtherIntangibleAssets | 35.00K | 2.63M | 3.03M | 3.45M |
| OtherIntangibleAssets | 2.63M | 3.03M | 3.45M | |
| NetPPE | 983.00K | 1.75M | 1.58M | 267.00K |
| AccumulatedDepreciation | -557.00K | -507.00K | -406.00K | |
| GrossPPE | 983.00K | 1.75M | 2.09M | 673.00K |
| Leases | 368.00K | 368.00K | 368.00K | |
| OtherProperties | 983.00K | 1.75M | 1.38M | |
| MachineryFurnitureEquipment | 323.00K | 343.00K | 305.00K | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 20.70M | 23.07M | 43.14M | 46.42M |
| OtherCurrentAssets | 527.00K | 5.58M | 286.00K | 756.00K |
| AssetsHeldForSaleCurrent | 2.30M | 0.00 | ||
| PrepaidAssets | 305.00K | 524.00K | 973.00K | |
| Inventory | 6.65M | 10.91M | 7.17M | 4.46M |
| Receivables | 5.32M | 5.16M | 7.41M | 15.69M |
| OtherReceivables | 3.26M | |||
| DuefromRelatedPartiesCurrent | 0.00 | 3.66M | 8.65M | |
| AccountsReceivable | 5.32M | 5.16M | 3.75M | 3.78M |
| AllowanceForDoubtfulAccountsReceivable | -200.00K | -200.00K | -100.00K | -18.00M |
| GrossAccountsReceivable | 5.51M | 5.36M | 3.85M | 21.78M |
| CashCashEquivalentsAndShortTermInvestments | 5.91M | 1.42M | 27.76M | 24.55M |
| OtherShortTermInvestments | 7.00K | 78.00K | 10.55M | 0.00 |
| CashAndCashEquivalents | 5.91M | 1.34M | 17.21M | 24.55M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -10.33M | -24.90M | -16.24M | -26.73M |
| RepaymentOfDebt | -4.32M | -21.34M | ||
| IssuanceOfDebt | 4.05M | 25.25M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 7.66M | 4.51M | 9.39M | 29.94M |
| CapitalExpenditure | -60.00K | -5.00K | -38.00K | -11.00K |
| InterestPaidSupplementalData | 1.73M | 147.00K | 1.00K | 2.00K |
| IncomeTaxPaidSupplementalData | 24.00K | 15.00K | 32.00K | 56.00K |
| EndCashPosition | 6.11M | 1.54M | 17.41M | 24.74M |
| BeginningCashPosition | 1.54M | 17.41M | 24.74M | 8.28M |
| ChangesInCash | 4.56M | -15.87M | -7.33M | 16.46M |
| FinancingCashFlow | 14.84M | 8.41M | 14.02M | 43.19M |
| CashFlowFromContinuingFinancingActivities | 14.84M | 8.41M | 14.02M | 43.19M |
| ProceedsFromStockOptionExercised | 7.44M | 0.00 | 4.63M | 13.25M |
| NetPreferredStockIssuance | 7.66M | 0.00 | ||
| PreferredStockIssuance | 7.66M | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 4.51M | 9.39M | 29.94M |
| CommonStockIssuance | 0.00 | 4.51M | 9.39M | 29.94M |
| NetIssuancePaymentsOfDebt | -265.00K | 3.90M | 0.00 | 0.00 |
| NetShortTermDebtIssuance | -265.00K | 3.90M | 0.00 | |
| ShortTermDebtPayments | -4.32M | -21.34M | ||
| ShortTermDebtIssuance | 4.05M | 25.25M | 0.00 | |
| NetLongTermDebtIssuance | 21.45M | 0.00 | 0.00 | |
| LongTermDebtIssuance | 21.45M | 0.00 | 0.00 | |
| InvestingCashFlow | -3.00K | 619.00K | -5.16M | -11.00K |
| CashFlowFromContinuingInvestingActivities | -3.00K | 619.00K | -5.16M | -11.00K |
| NetInvestmentPurchaseAndSale | 57.00K | 624.00K | -5.12M | 0.00 |
| SaleOfInvestment | 57.00K | 624.00K | 0.00 | |
| PurchaseOfInvestment | 0.00 | -5.12M | 0.00 | |
| NetIntangiblesPurchaseAndSale | -50.00K | 0.00 | ||
| PurchaseOfIntangibles | -50.00K | 0.00 | ||
| NetPPEPurchaseAndSale | -10.00K | -5.00K | -38.00K | -11.00K |
| PurchaseOfPPE | -10.00K | -5.00K | -38.00K | -11.00K |
| OperatingCashFlow | -10.27M | -24.89M | -16.20M | -26.71M |
| CashFlowFromContinuingOperatingActivities | -10.27M | -24.89M | -16.20M | -26.71M |
| ChangeInWorkingCapital | 6.21M | -4.39M | 2.79M | -1.50M |
| ChangeInOtherCurrentLiabilities | -689.00K | -657.00K | -781.00K | 0.00 |
| ChangeInOtherCurrentAssets | 5.16M | -5.16M | 0.00 | |
| ChangeInPayablesAndAccruedExpense | -2.04M | 64.00K | -2.69M | 11.71M |
| ChangeInAccruedExpense | -230.00K | -6.35M | -3.61M | 12.48M |
| ChangeInPayable | -1.81M | 6.42M | 912.00K | -773.00K |
| ChangeInAccountPayable | -1.81M | 6.42M | -773.00K | |
| ChangeInPrepaidAssets | -141.00K | 174.00K | 4.15M | -3.81M |
| ChangeInInventory | 4.23M | -3.75M | -2.81M | 2.59M |
| ChangeInReceivables | -313.00K | 4.93M | 4.92M | -12.00M |
| ChangesInAccountReceivables | -315.00K | -1.54M | -70.00K | -612.00K |
| OtherNonCashItems | 297.00K | -6.88M | -3.44M | -1.04M |
| StockBasedCompensation | 1.02M | 1.04M | 1.85M | 129.00K |
| UnrealizedGainLossOnInvestmentSecurities | 7.42M | -1.75M | 0.00 | |
| ProvisionandWriteOffofAssets | 162.00K | 122.00K | 206.00K | 77.00K |
| DepreciationAmortizationDepletion | 1.15M | 1.06M | 1.17M | 540.00K |
| DepreciationAndAmortization | 1.15M | 1.06M | 1.17M | 540.00K |
| AmortizationCashFlow | 329.00K | 418.00K | 418.00K | 418.00K |
| AmortizationOfIntangibles | 329.00K | 418.00K | 418.00K | 418.00K |
| Depreciation | 820.00K | 646.00K | 754.00K | 122.00K |
| OperatingGainsLosses | -1.35M | 4.28M | -16.39M | 12.80M |
| GainLossOnInvestmentSecurities | -1.67M | 4.28M | -16.39M | 12.80M |
| NetIncomeFromContinuingOperations | -17.76M | -20.13M | -640.00K | -37.71M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BFRI
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|